Status:
COMPLETED
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Observatoire Français de la sclérose en plaques (OFSEP)
Roche Diagnostic Ltd.
Conditions:
Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorders
Eligibility:
FEMALE
18-35 years
Brief Summary
CONTEXT A desire for pregnancy is common in young patients with multiple sclerosis (MS). The impact of MS on women fertility is debated, and the impact of disease-modifying therapies (DMTs) on fertili...
Eligibility Criteria
Inclusion
- Female
- Diagnosis of MS (including CIS) or NMOSD
- Aged 18 to 35 years old at blood sample collection
Exclusion
- Diagnosis of radiologically isolated syndrome (RIS)
- Age less than18 or more than 35.
- History of ovarian surgery
- Endometriosis
- Hypergonadotropin amenohrrea
- Any associated known autoimmune disease other than MS
- Previous MS treatment with immunosuppressive agents such as azathioprine, cyclophosphamide, mitoxantrone, bone marrow transplantation
- Previous treatment with gonadotoxic drugs (eg chemotherapy)
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 8 2024
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT07164924
Start Date
January 1 2018
End Date
December 8 2024
Last Update
September 10 2025
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France
2
CHU Besancon
Besançon, France
3
CHU Bordeaux
Bordeaux, France
4
CHU Caen
Caen, France